Taken together, these results suggest that LIGHT may be a stronger pathogenic driver in bacterial sepsis than in viral sepsis; given that both Apache III scores and mortality rates were higher in the bacterial sepsis, elevated Apache III scores could be considered an approach to identify patients that may have the most benefit from LIGHT neutralizing mAb therapy. The gene discussed is TNFSF14; the disease is bacterial infectious disease with sepsis.